Given investment horizon of 30 days, Flamel Technologies SA is expected to under-perform the Nektar. But the stock apears to be less risky and, when comparing its historical volatility, Flamel Technologies SA is 1.35 times less risky than Nektar. The stock trades about -0.54 of its potential returns per unit of risk. The Nektar Therapeutics is currently generating about -0.17 of returns per unit of risk over similar time horizon. If you would invest 787 in Nektar Therapeutics on April 26, 2012 and sell it today you would lose (91.00) from holding Nektar Therapeutics or give up 11.56% of portfolio value over 30 days.
Diversification
Significant diversification
Overlapping area represents amount of risk that can be diversified away by holding Flamel Technologies SA and Nektar Therapeutics in the same portfolio (assuming nothing else is changed)
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
